03-01-07

IFud$

PATENT

OIPE
FEB 27 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: KANEDA, YASUFUMI	EXAMINER: WHITEMAN, BRIAN A.
APPLICATION NO.: 10/824,757	ART UNIT: 1635
FILED: April 14, 2004	CONF. NO: 7091
FOR: VIRUS ENVELOPE VECTOR FOR GENE TRANSFER	

Information Disclosure Statement After First Office Action but Before Final Action or Notice of Allowance–37 CFR 1.97(c)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

    This information disclosure is being filed *after* three months of the filing date of this application or *after* the mailing date of the first office action on the merits, whichever occurred last, but *before* the mailing date of either a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, whichever occurs first. The references listed on the enclosed Form PTO-1449 may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

    ☒   Copies of references 1-10 are enclosed.

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

    This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

03/02/2007 LMONDIM1 00000031 502207 10824757
01 FC:1806   180.00 DA

4.   <u>Fee Payment (37 C.F.R. § 1.97(c)) or Certification (37 C.F.R. § 1.97(e))</u>

    ☒   Applicant elects to pay the fee under 37 C.F.R. § 1.17(p) $180.00.

        ☒   Please charge the deposit Account No. 50-2207 in the amount of $<u>180.00</u> covering the above fee.

        ☒   Please charge any underpayment for timely filing of this paper to Deposit Account No. 50-2207.

5.   <u>Patent Term Adjustment (37 C.F.R. § 1.704(d))</u>

    ☐   The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,
Perkins Coie LLP

Date: Feb. 27, 2007

Jacqueline F. Mahoney
Registration No. 48,390

Correspondence Address:
Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300

	Supplemental **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** Form PTO-1449 (Modified) (Use several sheets if necessary)	**COMPLETE IF KNOWN**	
		Application Number	10/824,757
		Filed	April 14, 2004
		First Named Inventor	Yasufumi Kaneda
		Group Art Unit	1635
		Examiner Name	Whiteman, B.
		Atty Dkt No.	59150-8010.US00
Sheet	1 of 1	Confirmation No.	7091

OIPE
FEB 27 2007
PATENT & TRADEMARK OFF

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent or Application NUMBER	Kind Code (if known)	Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initial	Cite No.	Foreign Patent or Application — Office	NUMBER	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	T

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	1.	Cotten *et al.*, "Psoralen Treatment of Adenovirus Particles Eliminates Virus Replication and Transcription While Maintaining the Endosomolytic Activity of the Virus Capsid", *Virology*, 205254-261 (1984).	
	2.	Hangai *et al.*, "In Vivo Delivery of Phosphorothioate Oligonucleotides Into Murine Retina", *Arch Ophthalmol.*, 116:342-348 (1998).	
	3.	Kim *et al.* "Effect of Lipid Compositions on Gene Transfer into 293 Cells Using Sendai F/HN-Virosomes", *Journal of Biochemistry and Molecular Biology*, 35(5):459-464 (2002).	
	4.	Nakanishi *et al.*, "Glycoproteins of Sendai Virus (HVJ) Have A Critical Ratio for Fusion Between Virus Envelopes and Cell Membranes", *Exp Cell Research*, pgs. 143-151(1982).	
	5.	Nakanishi *et al.*, "Preparation of Unilamellar Fusogenic Liposomes Using the Sendai Virus", *Folia Pharmacol. Jpn.*, 112:299-305 (English Abstract) (1998).	
	6.	Otsuji *et al.*, "In Vivo Gene Transfer into Choroidal Neovascularization by the HVJ Liposome Method", *Graefe's Arch Clin Exp Ophthalmol*, 238:191-199 (2000).	
	7.	Paternostre *et al.*, "Solubilization and Reconstitution of Vesicular Stomatitis Virus Envelope Using Octylglucoside" *Biophysical Journal*, 72:1683-1694 (1997).	
	8.	Race *et al.*, "A Multistep Procedure for the Chemical Inactivation of Human Immunodeficiency Virus for Use as an Experimental Vaccine", *Vaccine*, 13(15):1567-1575 (1995).	
	9.	Saeki *et al.*, "Development and Characterization of Cationic Liposomes Conjugated with HVJ (Sendai Virus): Reciprocal Effect of Cationic Lipid for *In Vitro and In Vivo* Gene Transfer", *Human Gene Therapy*, 8:2133-2141 (1997).	
	10.	Vainstein *et al.*, "A New Method for Reconstitution of Highly Fusogenic Sendai Virus Envelopes", *Biochimica et Biophysica ACTA*, 773:184-188 (1984).	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).